31 results about "Diffuse large cell lymphoma" patented technology

The invention relates to the field of anti-tumor drugs, and discloses an anti-diffuse large B-cell lymphoma pharmaceutical composition, a preparation method and application thereof, the composition comprises azacitidine and Sanilisoma, the composition can improve the accumulation amount of VDUP1 protein in a cell nucleus through the combination of the methylation effect of DNMT3b on VDUP1 protein and the inhibition of XPO1 activity by Sanilisoma, and the anti-diffuse large B-cell lymphoma pharmaceutical composition can be used for preparing anti-diffuse large B-cell lymphoma. The chemotherapy effect is remarkably improved, the sensitivity of the DLBCL to the Sanisole is remarkably improved, and particularly, the pharmaceutical composition has a remarkable curative effect on R / R DLBCL patients.

The invention relates to the technical field of biomedicine, in particular to a molecular target for treating recurrent refractory diffuse large B-cell lymphoma and application of the molecular target. According to the invention, a molecular target CSNK1E for treating recurrent refractory diffuse large B-cell lymphoma is excavated; compared with existing traditional targets of other drugs for recurrent lymphoma, the CSNK1E has a remarkable expression difference in the recurrent DLBCL, and it is indicated that the CSNK1E possibly has more remarkable advantages in treatment of the recurrent DLBCL.

This disclosure provides a method for treating lymphoma, the method comprising administering a bispecific CD20xCD3 antibody to a patient in need, wherein the patient is selected based on an improvement in the level of circulating tumor (ct) DNA. In some embodiments, this disclosure provides a method for identifying lymphoma patients who may respond well to a therapy comprising a bispecific CD20xCD3 antibody.

The invention discloses a method for screening a B-cell lymphoma biomarker, and belongs to the technical field of bioinformatics. The invention aims to provide a more accurate and simple method for screening the B-cell lymphoma biomarker. The invention provides a method for screening a B cell lymphoma biomarker. The relation between the infiltration ratio of all cell subgroups of T / NK and myeloid cells and the lifetime of a patient is screened out by utilizing scRNA-seq data of Burki lymphoma, diffuse large B cell lymphoma, follicular lymphoma and spleen marginal region lymphoma and bulk RNA-seq data of a Burki lymphoma and diffuse large B cell lymphoma database. And a theoretical basis is provided for screening survival analysis of lymphoma diseases.

Provided is a method for diagnosing the prognosis and therapeutic effect for chemotherapy in patients with rheumatoid arthritis-associated lymphoproliferative disorder (RA-LPD), who have developed a lymphoproliferative disorder (LPD) during the treatment of rheumatoid arthritis (RA). This is a kit for diagnosing the prognosis and therapeutic effect for chemotherapy in rheumatic arthritis-associated lymphoproliferative disorder (RA-LPD) patients, who have developed LPD during RA treatment. The kit comprises: means for detecting an inositol 1,4,5-triphosphate receptor (ITPR) type 2 (ITPR2) gene mutation in a biological sample from a patient; and instructions for determining that the prognosis and therapeutic effect for chemotherapy are poor when an ITPR2 gene mutation is present in the biological sample from the patient. The LPD is diffuse large B-cell lymphoma (DLBCL). For the ITPR2 gene mutation, Chr12:rs26744460 is GT or GG. Use for the diagnosis of non-RA lymphoma patients is also possible.

The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of lymphoma (e.g., a diffuse large B-cell lymphoma (e.g., a germinal-center B-cell-like or activated B-cell-like diffuse large B-cell lymphoma). The invention is based, at least in part, on the discovery that macrophage biomarkers are useful in methods of identifying, diagnosing, or predicting the therapeutic efficacy of treatment with an anti-CD79b immunoconjugate (e.g., polatuzumab vedotin) and an anti-CD20 antibody (e.g., obinutuzumab or rituximab).

The present invention relates to methods of treating previously untreated diffuse large B-cell lymphoma (DLBCL), which is defined as high risk according to circulating tumor DNA (ctDNA), by administering gphentumab and in combination with chemotherapy.

The application discloses a recombinant oncolytic virus rVSV M51R The application of C in hepatitis B liver cancer belongs to the field of biological medicine. The recombinant oncolytic virus is a recombinant attenuated vesicular stomatitis virus carrying an HBV HBcAg gene and having an M-R mutation at the 51st amino acid of the M gene. The recombinant oncolytic virus is proved to have a curative effect in a tumor model, and can be used for preparing a therapeutic vaccine for HBV-positive liver cancer, HBV-positive diffuse large B-cell lymphoma and other HBV-positive tumors.

The application discloses a method for screening B-cell lymphoma biomarkers and belongs to the technical field of bioinformatics. The application aims to provide a more accurate and simple method for screening B-cell lymphoma biomarkers. The application provides a method for screening B-cell lymphoma biomarkers, which utilizes scRNA-seq data of Burkitt lymphoma, diffuse large B-cell lymphoma and follicular lymphoma, splenic marginal zone lymphoma and bulk RNA-seq data of Burkitt lymphoma and diffuse large B-cell lymphoma database to screen the relationship between T / NK and myeloid cells all cell subpopulation infiltration ratio and patient survival period. The application provides a theoretical basis for screening lymphoma disease survival analysis.

The invention discloses a PET-CT medical image automatic segmentation method based on weak supervised learning, and the method comprises the steps: firstly obtaining original images of PET and CT modes, and carrying out the registration and resampling; secondly, establishing a PET-CT medical image segmentation network model based on weak supervised learning; then, establishing a point annotation data set based on the diffuse large B-cell lymphoma, and performing pseudo-label generation on the data set by using a multi-modal fusion pseudo-label generation algorithm; then, the PET image, the CT image and the pseudo tag are sent to the segmentation network model for training, and optimal parameters are stored; and finally, performing prediction segmentation on the target focus by using the optimal model. According to the method, the segmentation network model is trained by using the labels in a weak form, so that the dependence of an existing medical image segmentation algorithm on accurate annotation data is reduced.

The invention discloses a composition for treating ABC type diffuse large B-cell lymphoma and application of the composition, and relates to the technical field of biological medicine. The composition comprises the chidamide and the hispidulin. According to the invention, a synergistic treatment system of the composition chidamide and hispidulin is constructed, and the problem of treatment of ABC type diffuse large B-cell lymphoma is accurately solved. According to the composition, through targeting double key targets of HDAC3 and PIM1, the synergistic interaction of epigenetic regulation and signal channel inhibition is realized, and the anti-tumor effect is remarkably improved. The invention successfully breaks through the bottleneck that the existing R-CHOP scheme is poor in curative effect and easy to relapse in the treatment of ABC subtype lymphoma, provides a brand new high-specificity treatment strategy for relapse or refractory ABC type diffuse large B-cell lymphoma, and has a wide clinical application prospect.

The present application relates to a kind of combination drug composition for preventing or treating diffuse large B-cell lymphoma and its application, the active component of the combination drug composition is composed of first active component and second active component;The first active component is selected from selinexor or any one or at least two combinations of its pharmaceutically acceptable salt, isomer, solvate, metabolite;The second active component is selected from ritonavir or any one or at least two combinations of its pharmaceutically acceptable salt, isomer, solvate, metabolite.The combination drug composition has excellent treatment effect of diffuse large B-cell lymphoma, not only can reduce the dosage of selinexor, improve the safety of drug, but also has more significant inhibitory effect on diffuse large B-cell lymphoma than using single selinexor.

The invention is related to a method of treating a subject with acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, non-Hodgkin's lymphoma, Burkitt lymphoma, or diffuse large B-cell lymphoma, or myelodysplastic syndrome by administration of Compound (I): (I), or a pharmaceutically acceptable salt thereof.

The present invention relates to a method and a kit for the diagnosis, prognosis, and / or stratification of diffuse large B-cell lymphoma (DLBCL).

Disclosed herein is a method for treating cancer in a subject in need thereof, the method comprising administering (a) an IL-2 conjugate and (b) chimeric antigen receptor (CAR) therapy. Also disclosed herein is a method for treating diffuse large B-cell lymphoma (DLBCL) in a subject in need thereof, the method comprising administering an IL-2 conjugate.

The invention belongs to the technical field of biomedicine, and particularly relates to application of SDAD1 as a target spot to preparation of a medicine for treating diffuse large B-cell lymphoma. The invention provides a biomarker SDAD1 gene or SDAD1 protein for auxiliary diagnosis of diffuse large B-cell lymphoma for the first time. The invention discovers that the progression-free lifetime and the total lifetime of patients with high SDAD1 expression are obviously shortened compared with those of patients with low expression for the first time, which prompts that the high expression of SDAD1 is related to poor prognosis of DLBCL patients. The LC1-DNAzyme drug capable of efficiently inhibiting SDAD1 gene expression is prepared, the effects of specifically recognizing DLBCL cells, inhibiting tumor cell proliferation and promoting tumor cell apoptosis can be achieved, and it is verified through a mouse tumor-bearing model that the drug can effectively treat lymphoma and is good in safety.

The present invention relates to an in vitro or ex vivo diagnostic method for the survival chances of a patient with diffuse large-scale B-cell lymphoma (DLBCL) comprising a step of detecting the expression of at least one of the newly identified DLBCL biomarker genes.

The application relates to application of TNFRSF13B in preparation of a medicine for treating relapsed refractory diffuse large B-cell lymphoma. Research finds that TNFRSF13B has specific expression in relapsed refractory diffuse large B-cell lymphoma and is closely related to the survival of DLBCL patients, in-vitro cell experiments and in-vivo animal experiments verify that TNFRSF13B plays an important role in maintaining the clonal formation ability, continuous passage proliferation and doxorubicin resistance phenotype, and the blocking can significantly inhibit the tumor initiation ability, which indicates potential application value of TNFRSF13B in diagnosis, prognosis evaluation and treatment of relapsed refractory diffuse large B-cell lymphoma.

Aspects of the disclosure relate to methods for determining whether or a subject is likely to respond to certain adoptive cell therapies (e.g., chimeric antigen receptor (CAR) T-cell therapy, etc.). In some embodiments, the methods comprise the steps of identifying a subject as having a tumor microenvironment (TME) type based upon a molecular-functional (MF) expression signature of the subject, and determining whether or not the subject is likely to respond to a chimeric antigen receptor (CAR) T-cell therapy based upon the TME type. In some embodiments, the methods comprise determining the lymphoma microenvironment (LME) type of a lymphoma (e.g., Diffuse Large B cell lymphoma (DLBCL)) subject and identifying the subjects prognosis based upon the LME type determination.

The present disclosure provides anti-CD180 binding molecules and uses thereof. In one embodiment, the anti-CD180 binding molecule is an anti-CD180 antibody. Also provided is an anti-CD180 antibody-drug conjugate (ADC) comprising a monoclonal antibody or antigen-binding fragment thereof that targets CD180-highly expressing tumors, a cytotoxic drug payload, and a linker moiety that conjugates the antibody or antigen-binding fragment thereof that targets CD180-highly expressing tumors to the cytotoxic drug payload. The anti-CD180 antibody or antigen-binding fragment thereof, and the ADC comprising the anti-CD180 antibody or antigen-binding fragment thereof, are useful in treating diseases such as acute myeloid leukemia, mantle cell lymphoma, multiple myeloma, follicular lymphoma, acute B-lymphoblastic leukemia, or diffuse large B-cell lymphoma.

The present invention relates to combination therapies employing an anti-CD20 / anti-CD3 bispecific antibody in combination with an anti-CD19 / anti-CD28 bispecific antibody and a CD19-targeted 4-1BB (CD137) agonist and the use of these combination therapies for the treatment of B-cell cancer such as diffuse large B cell lymphoma (DLBCL).

The disclosure provides cells comprising CD19-directed chimeric antigen receptor (CAR) genetically modified autologous T cell immunotherapy for the treatment of, e.g., relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. Some aspects of the disclosure relate to methods of treatment and monitoring following infusion of T cell therapy provided herein.

The present disclosure relates to compositions and methods for the diagnosis and treatment or prevention of DLBCL. In particular, the instant disclosure provides a DLBCL classifier that has identified at least five distinct classes of DLBCL cancer, each of which possesses distinct pathogenic mechanisms and outcomes. The instant classifier identifies preferred therapeutic options (including combination therapies) for each such class of DLBCL cancer.

The application discloses a novel IRAK4 inhibitor compound shown in formula (I) and use of the compound for preventing or treating IRAK4-mediated diseases, which include but are not limited to rheumatoid arthritis, lupus erythematosus and other autoimmune diseases, activated B-cell-like diffuse large B-cell lymphoma, chronic lymphocytic leukemia, relapsed non-Hodgkin's lymphoma and other lymphomas.

The present invention provides diagnostic methods, therapeutic methods, and therapeutic compositions for lymphoma (e.g., diffuse large B-cell lymphoma (e.g., hair center B-cell-like or activated B-cell-like diffuse large B-cell lymphoma). The present invention is based, at least in part, on the discovery that macrophage biomarkers can be used in methods for identifying, diagnosing, or predicting the efficacy of treatment with an anti-CD79b immunoconjugate (e.g., vipostuzumab) and an anti-CD20 antibody (e.g., ototuzumab or rituximab).

The application relates to the field of biomedical technology, in particular to a model for diffuse large B-cell lymphoma (DLBCL) prognosis evaluation and application thereof, in particular to a tumor-infiltrating clonal hematopoiesis mutation analysis method and application thereof in DLBCL prognosis evaluation and personalized treatment. The model is constructed based on tumor-infiltrating clonal hematopoiesis mutation characteristics, can more effectively and accurately identify a DLBCL patient subpopulation with high recurrence and high mortality risk, thereby providing reliable basis for early implementation of intensified treatment or targeted intervention in the clinic, and has significant clinical value and social benefits.

The application provides application of NCBP1 as an auxiliary diagnosis and / or prognosis marker of diffuse large B-cell lymphoma (DLBCL), and belongs to the technical field of medicinal biology and molecular biology. The application first discovers that NCBP1 is highly expressed in DLBCL patients, the high expression of NCBP1 has a significant influence on the proliferation of DLBCL cells, and is related to poor prognosis; NCBP1 enhances the proliferation of DLBCL cells in a METTL3-dependent manner, NCBP1 enhances the m6A catalytic function of METTL3 by maintaining the stability of the oncogene METTL3 mRNA; the NCBP1 / METTL3 / m6A / c-MYC axis may be a mechanism for the development of DLBCL, which provides a new idea for molecular targeted therapy of DLBCL, enriches the understanding of the m6A modification system in DLBCL, and has important clinical application value.

The present invention relates to an in vitro or ex vivo diagnostic method for the survival chances of a patient with diffuse large-scale B-cell lymphoma (DLBCL) comprising a step of detecting the expression of at least one of the newly identified DLBCL biomarker genes.

The present invention relates to a combination therapy that combines an anti-CD20 / anti-CD3 bispecific antibody with an anti-CD19 / anti-CD28 bispecific antibody and a CD19-targeted 4-1BB (CD137) agonist, and the use of this combination therapy for the treatment of B-cell cancers, such as diffuse large B-cell lymphoma (DLBCL).